Biosimilar/Brand Patent Settlements Need US Antitrust Review, PBM Says
Executive Summary
Federal Trade Commission and Department of Justice should be able to scrutinize settlements between biologic reference product sponsors and biosimilar developers, Express Scripts says; PBM's policy proposals for coming year include safe harbor for certain value-based reimbursement arrangements, and mandatory electronic prescribing and dispensing limits for opioids.
You may also be interested in...
Biosimilars To Be Subject To Same Pay-For-Delay Deal Reporting As Generics
Legislation headed to President Trump would also ban pharmacy "gag" clauses.
Biosimilars To Be Subject To Same Pay-For-Delay Deal Reporting As Generics
Legislation headed to President Trump would also ban pharmacy "gag" clauses.
The New 180 Days? Humira Biosimilar Deals Give Amgen 150-Day Jump On Samsung
If approved in the US, Samsung Bioepis' adalimumab biosimilar may launch June 30, 2023, five months after the market entry date for Amjevita under Amgen's agreement with AbbVie; the 150-day marketing advantage for the first biosimilar approved suggests a benchmark for future patent litigation settlements.